Sugi Predict

Sugi Predict / Compounds / SCHEMBL1785144

SCHEMBL1785144

SCHEMBL1785144

CC(C)(C)OC(=O)N1CCC[C@H](COS(C)(=O)=O)C1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 1/20 0.53
▸ MEN1 O00255 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ GLS O94925 2/20 0.45
▸ BACE1 P56817 2/20 0.44
▸ HPGD P15428 1/20 0.44
▸ ACKR3 P25106 1/20 0.44
▸ CTSD P07339 1/20 0.44
▸ FEN1 P39748 2/20 0.42
▸ KAT7 O95251 1/20 0.42
▸ KAT8 Q9H7Z6 1/20 0.42
▸ ALOX5AP P20292 1/20 0.42
▸ KDM1A O60341 1/20 0.42
▸ CHEK2 O96017 1/20 0.42
▸ NR1H2 P55055 1/20 0.42
▸ GPR119 Q8TDV5 3/20 0.41
▸ BCHE P06276 2/20 0.41
▸ HTR6 P50406 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1785143 1.00 SCN9A (0.53) SCN9AMEN1ALDH1A1MAPTKMT2A
SCHEMBL2955344 1.00 SCN9A (0.53) SCN9AMEN1ALDH1A1MAPTKMT2A
SCHEMBL3713816 0.97 SCN9A (0.52) SCN9AMEN1ALDH1A1MAPTKMT2A
SCHEMBL624013 0.97 SCN9A (0.54) SCN9AMEN1ALDH1A1MAPTKMT2A
SCHEMBL31420855 0.96 SCN9A (0.50) SCN9AMEN1ALDH1A1MAPTKMT2A
SCHEMBL31421097 0.96 SCN9A (0.50) SCN9AMEN1ALDH1A1MAPTKMT2A
SCHEMBL707476 0.95 SCN9A (0.50) SCN9AMEN1ALDH1A1MAPTKMT2A
SCHEMBL613606 0.92 GPR119 (0.47) SCN9AMEN1ALDH1A1MAPTKMT2A
SCHEMBL2241775 0.92 GPR119 (0.47) SCN9AMEN1ALDH1A1MAPTKMT2A
SCHEMBL613607 0.92 GPR119 (0.47) SCN9AMEN1ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4646414-A1 CDK2 INHIBITORS Blueprint Medicines Corporation (US) 2025-11-12 — — EP disclosed
EP-4616913-A2 GCN2 INHIBITORS AND USES THEREOF Merck Patent GmbH (DE) 2025-09-17 — — EP disclosed
EP-3746075-B1 GCN2 INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2025-09-03 — — EP disclosed
US-20250270191-A1 QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2025-08-28 — — US disclosed
EP-3782994-B1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY INC (US) 2025-07-16 — — EP disclosed
EP-4536649-A1 QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2025-04-16 — — EP disclosed
US-20250090500-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS LOXO ONCOLOGY, INC. 2025-03-20 — — US disclosed
US-12220401-B2 Compounds useful as kinase inhibitors LOXO ONCOLOGY, INC. (US) 2025-02-11 — — US disclosed
WO-2024148091-A1 CDK2 INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2024-07-11 — — WO disclosed
CN-118005640-A GCN2 inhibitors and uses thereof 默克专利股份有限公司 2024-05-10 — — CN disclosed
WO-2005077463-A2 LIGAND FOR A MONOAMINE RECEPTOR OR TRANSPORTER FOR TREATING ADDICTION OR DEPENDENCE SEPRACOR INC. (US) 2005-08-25 — — WO disclosed
US-20050080078-A1 Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter SEPRACOR, INC. (US) 2005-04-14 — — US disclosed
US-6809108-B1 SELECTIVE MUSCARINIC M3 RECEPTOR ANTAGONTS; REDUCED SIDE EFFECTS BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-10-26 — — US disclosed
US-20040204369-A1 Novel amide derivatives MSD K.K. (JP) 2004-10-14 — — US disclosed
US-20040077706-A1 Ligands for monoamine receptors and transporters, and methods of use thereof AQUILA BRIAN M (US) 2004-04-22 — — US disclosed
EP-1213281-B1 NOVEL AMIDE DERIVATIVES BANYU PHARMA CO LTD (JP) 2004-02-18 — — EP disclosed
EP-1318988-A2 LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF (NEUROTRANSMISSION) Sepracor, Inc. (US) 2003-06-18 — — EP disclosed
US-20030050309-A1 Ligands for monoamine receptors and transporters, and methods of use thereof SEPRACOR INC. 2003-03-13 — — US disclosed
EP-1213281-A1 NOVEL AMIDE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-06-12 — — EP disclosed
WO-2002022572-A2 LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF (NEUROTRANSMISSION) SEPRACOR, INC. (US) 2002-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080078-A1 Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter PNMT, TAAR1, OPRL1 SCN9A 3135/4885MEN1 4263/4885ALDH1A1 279/4885
US-20040204369-A1 Novel amide derivatives CHRM3, CHRM1, CHRM2 SCN9A 2030/4885MEN1 490/4885ALDH1A1 1744/4885
US-12220401-B2 Compounds useful as kinase inhibitors BTK, ABL1, LCK SCN9A 3950/4885MEN1 2243/4885ALDH1A1 4454/4885
US-20030050309-A1 Ligands for monoamine receptors and transporters, and methods of use thereof SLC6A2, OPRL1, SLC18A2 SCN9A 1553/4885MEN1 638/4885ALDH1A1 873/4885
US-20250090500-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, ABL1, LCK SCN9A 3950/4885MEN1 2243/4885ALDH1A1 4454/4885
US-20250270191-A1 QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR SCN9A 4521/4885MEN1 1552/4885ALDH1A1 291/4885
US-20040077706-A1 Ligands for monoamine receptors and transporters, and methods of use thereof SLC6A2, OPRL1, SLC18A2 SCN9A 1553/4885MEN1 638/4885ALDH1A1 873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.